CN113209000B - 用于药物递送和保护眼睛前段的眼用制剂 - Google Patents

用于药物递送和保护眼睛前段的眼用制剂 Download PDF

Info

Publication number
CN113209000B
CN113209000B CN202110452774.8A CN202110452774A CN113209000B CN 113209000 B CN113209000 B CN 113209000B CN 202110452774 A CN202110452774 A CN 202110452774A CN 113209000 B CN113209000 B CN 113209000B
Authority
CN
China
Prior art keywords
active agent
months
compound
formulation
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110452774.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113209000A (zh
Inventor
D·P·宾加曼
P·G·查尼
M·B·瓦克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panoptica Inc
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of CN113209000A publication Critical patent/CN113209000A/zh
Application granted granted Critical
Publication of CN113209000B publication Critical patent/CN113209000B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110452774.8A 2014-09-17 2015-09-17 用于药物递送和保护眼睛前段的眼用制剂 Active CN113209000B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
US62/051794 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye
CN201580049902.7A CN106999476B (zh) 2014-09-17 2015-09-17 用于药物递送和保护眼睛前段的眼用制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580049902.7A Division CN106999476B (zh) 2014-09-17 2015-09-17 用于药物递送和保护眼睛前段的眼用制剂

Publications (2)

Publication Number Publication Date
CN113209000A CN113209000A (zh) 2021-08-06
CN113209000B true CN113209000B (zh) 2025-05-13

Family

ID=55453708

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110452774.8A Active CN113209000B (zh) 2014-09-17 2015-09-17 用于药物递送和保护眼睛前段的眼用制剂
CN201580049902.7A Active CN106999476B (zh) 2014-09-17 2015-09-17 用于药物递送和保护眼睛前段的眼用制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580049902.7A Active CN106999476B (zh) 2014-09-17 2015-09-17 用于药物递送和保护眼睛前段的眼用制剂

Country Status (19)

Country Link
US (6) US9814702B2 (cg-RX-API-DMAC7.html)
EP (2) EP3193867B1 (cg-RX-API-DMAC7.html)
JP (3) JP6657193B2 (cg-RX-API-DMAC7.html)
KR (2) KR102555091B1 (cg-RX-API-DMAC7.html)
CN (2) CN113209000B (cg-RX-API-DMAC7.html)
AU (2) AU2015317531B2 (cg-RX-API-DMAC7.html)
CA (1) CA2958315A1 (cg-RX-API-DMAC7.html)
DK (1) DK3193867T3 (cg-RX-API-DMAC7.html)
ES (2) ES3010497T3 (cg-RX-API-DMAC7.html)
HU (1) HUE053852T2 (cg-RX-API-DMAC7.html)
IL (2) IL282504B (cg-RX-API-DMAC7.html)
MA (1) MA56220A (cg-RX-API-DMAC7.html)
MX (2) MX383792B (cg-RX-API-DMAC7.html)
NZ (1) NZ767710A (cg-RX-API-DMAC7.html)
PL (1) PL3193867T3 (cg-RX-API-DMAC7.html)
PT (1) PT3193867T (cg-RX-API-DMAC7.html)
RU (2) RU2768652C1 (cg-RX-API-DMAC7.html)
WO (1) WO2016044671A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701303B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768652C1 (ru) * 2014-09-17 2022-03-24 Паноптика, Инк. Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
SG11201907400YA (en) * 2018-07-18 2020-02-27 Univ Wenzhou Medical Method for treating myopia and application in preparation of medicament
TW202033213A (zh) * 2018-10-24 2020-09-16 美商雅利斯塔製藥公司 脂聯素擬肽調配物
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
WO2013126799A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998925A4 (en) * 1997-05-26 2003-02-26 New Vision Co Ltd TOPICAL ADMINISTRATION COMPOSITIONS CONTAINING VITAMINS D AND VITAMINS K
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
KR20050116401A (ko) * 2000-11-28 2005-12-12 화이자 프로덕츠 인크. 이소티아졸-4-카복사미드의 염 및 과증식-억제제로서의그의 용도
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
EP1814540A2 (en) * 2004-11-16 2007-08-08 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
KR20110123789A (ko) * 2009-03-03 2011-11-15 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
CA2770894A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
RU2012117898A (ru) * 2009-09-30 2013-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Кофакторы и способы их применения индивидуумами
WO2012012404A1 (en) * 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2808628A1 (en) * 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20140161720A1 (en) * 2011-05-26 2014-06-12 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
DK2779994T3 (da) * 2011-11-15 2020-05-18 Allergan Inc Suspensioner af cyclosporin a form 2
CN105142686B (zh) 2013-03-14 2020-04-10 帕恩欧普佳有限公司 给药于眼后段的眼用制剂
RU2768652C1 (ru) * 2014-09-17 2022-03-24 Паноптика, Инк. Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
WO2013126799A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Also Published As

Publication number Publication date
US20210275501A1 (en) 2021-09-09
ES2863601T3 (es) 2021-10-11
MX2017003436A (es) 2017-07-28
RU2017112930A (ru) 2018-10-17
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
KR20220137157A (ko) 2022-10-11
IL282504A (en) 2021-06-30
WO2016044671A1 (en) 2016-03-24
EP3878449A1 (en) 2021-09-15
ES3010497T3 (en) 2025-04-03
US9623011B2 (en) 2017-04-18
NZ729142A (en) 2023-08-25
RU2704810C2 (ru) 2019-10-31
US20160074371A1 (en) 2016-03-17
US20240277674A1 (en) 2024-08-22
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
ZA201701303B (en) 2021-07-28
KR102450020B1 (ko) 2022-09-30
RU2768652C1 (ru) 2022-03-24
EP3193867B1 (en) 2021-01-20
DK3193867T3 (da) 2021-04-06
JP6657193B2 (ja) 2020-03-04
CN106999476B (zh) 2021-05-04
IL282504B (en) 2022-08-01
IL251019B (en) 2021-05-31
AU2015317531B2 (en) 2020-11-19
MA56220A (fr) 2022-04-20
US10183014B2 (en) 2019-01-22
US9814702B2 (en) 2017-11-14
NZ767710A (en) 2023-09-29
KR20170058976A (ko) 2017-05-29
JP6890692B2 (ja) 2021-06-18
US20160206599A1 (en) 2016-07-21
JP7176042B2 (ja) 2022-11-21
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
CN106999476A (zh) 2017-08-01
US20180078531A1 (en) 2018-03-22
PL3193867T3 (pl) 2021-07-12
MX383792B (es) 2025-03-14
KR102555091B1 (ko) 2023-07-13
US20190314343A1 (en) 2019-10-17
EP3193867A4 (en) 2018-05-02
JP2017527600A (ja) 2017-09-21
JP2021121624A (ja) 2021-08-26
IL251019A0 (en) 2017-04-30
PT3193867T (pt) 2021-03-09
JP2020079274A (ja) 2020-05-28
AU2021200997A1 (en) 2021-03-11
RU2017112930A3 (cg-RX-API-DMAC7.html) 2019-04-11
HUE053852T2 (hu) 2021-07-28
EP3878449B1 (en) 2024-10-30
MX2021006070A (es) 2021-07-06

Similar Documents

Publication Publication Date Title
CN105142686B (zh) 给药于眼后段的眼用制剂
US20240277674A1 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40059709A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40060903B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40060903A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK1236824A1 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK1236824B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059709

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant